|
gptkbp:instanceOf
|
gptkb:drug
androgen receptor inhibitor
|
|
gptkbp:approvalYear
|
2012
|
|
gptkbp:approvedBy
|
gptkb:FDA
gptkb:EMA
|
|
gptkbp:ATCCode
|
L02BB04
|
|
gptkbp:brand
|
gptkb:Xtandi
|
|
gptkbp:CASNumber
|
915087-33-1
|
|
gptkbp:chemicalFormula
|
C21H16F4N4O2S
|
|
gptkbp:contraindication
|
pregnancy
women of childbearing potential
|
|
gptkbp:developer
|
gptkb:Astellas_Pharma
gptkb:Medivation
|
|
gptkbp:drugInteraction
|
gptkb:warfarin
CYP2C8 inhibitors
CYP3A4 inducers
|
|
gptkbp:eliminationHalfLife
|
5.8 days
|
|
gptkbp:hasSMILES
|
O=C(NC1=CC=C(C=C1)C2=NC=CS2)C3=CC=C(C=C3)N4C=C(C(F)(F)F)C=C4F
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
enzalutamide
|
|
gptkbp:indication
|
metastatic castration-resistant prostate cancer
non-metastatic castration-resistant prostate cancer
|
|
gptkbp:KEGGID
|
D09716
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
androgen receptor antagonist
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:molecularWeight
|
464.44 g/mol
|
|
gptkbp:patentExpired
|
2027 (US)
|
|
gptkbp:pregnancyCategory
|
gptkb:X_(US)
|
|
gptkbp:PubChem_CID
|
13016713
15951529
CHEMBL1079510
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
fatigue
hypertension
seizures
hot flashes
|
|
gptkbp:UNII
|
7LKK855W8I
|
|
gptkbp:usedFor
|
prostate cancer
|
|
gptkbp:bfsParent
|
gptkb:Medivation
|
|
gptkbp:bfsLayer
|
5
|